# LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer

Source: https://onco.cc/trials/nct06387628/  
OnCo record `nct06387628` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of LM-108, toripalimab, eribulin and nab-paclitaxel in triple-negative breast cancer, run by Fudan University, now recruiting.

## Summary

LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer is a phase 2, interventional study registered as NCT06387628 by Fudan University, with a registry enrolment figure of 74 participants, started 2024-07-10 and due to reach its primary completion in 2026-04-01. Interventions recorded: LM-108; Toripalimab; Eribulin; Nab paclitaxel. Conditions listed: TNBC - Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Unresectable or metastatic or postoperative recurrent, histologically confirmed advanced triple-negative breast cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT06387628
- Phase: 2
- Setting: A Phase II Single Center Two Cohorts Trial of LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer
- Sponsor: Fudan University
- Enrolled: 74

## Sources

- ClinicalTrials.gov NCT06387628: https://clinicaltrials.gov/study/NCT06387628

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Eribulin](https://onco.cc/drugs/eribulin/), [LM-108](https://onco.cc/drugs/lm-108/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06387628.json